📢 #ASCO20 Virtual Scientific Program 👉 Friday, May 29-Sunday, May 31. Learn & collab across a variety of approaches, disciplines, and specialties w an engaging lineup of virtual scientific content fal.cn/37yEF

Cancer clinical trials, are the gold standard in treatment of patients with cancer, but often do involve more MD or RB visits, Lancet insight below...

To keep on radar — like the term “not negatives” jamanetwork.com/journals/jamao…

IO has made IAEs the “GVHD” of solid malignancies. ja.ma/2Sos6XO

forbes.com/sites/robertgl… collateral damage - well said. Need to adjust to new normal quickly as to limited the lasting impact this will have

Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients Read for free! bit.ly/3tqMzfE #Quantitativeimaging #Stroma #BreastCancer

Chemotherapy does not increase COVID-19 risk vs. noncytotoxic therapies for breast cancer healio.com/news/hematolog…

Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment - The ASCO Post ascopost.com/news/june-2021…

cattendee.abstractsonline.com/meeting/1042

Despite initial fairly negative Fda review — now approved. IO metrics will differ from conventional therapy, pCR inc/ EFS shines. Will be a theme

Medical oncologist Nina D’Abreo leads a trial for HER2-positive #breastcancer to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab.  Learn more: bit.ly/3BtEKKo

FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer onclive.com/view/fda-appro… via OncLive.com. Targeted therapies for adjuvant management of high risk TNBC — IO and now germline pts with PARP. Great to see the needle moving.

Our cancer experts just published in The Oncologist on the outcomes of breast cancer patients being treated during the #COVID19 pandemic. Read more about the findings from this study: bit.ly/3IVDuCM

Glad no longer in this phase of the pandemic! Grateful to my colleagues for working with me on this! This one is dedicated to our patients who bravely navigated their diagnoses amid the uncertainty of the early pandemic Perlmutter Cancer Center at NYU Langone Health @perlmutterproud academic.oup.com/oncolo/article…

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy... sciencedirect.com/science/articl… Columbia colleagues, continue the multiplex in her2 . Similar findings across Non-luminal subtypes

Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC onclive.com/view/trastuzum… via OncLive.com. While most oncs who prev rx TDxd are not surprised, still so impressed! Best said, these are modular drugs. Homerun here, and more to come #ADC #ASCO22

Join our medical oncologist Dr. Douglas Marks on Doctor Radio, tomorrow, August 2 at 9 am ET as he discusses the updated ASCO guidelines on optimal adjuvant chemotherapy and targeted therapy for breast cancer. SiriusXM (Channel 110).

TALENT Trial - hinting at the beginning of the end of cytotoxic chemotherapy. With targeted chemotherapy by ADC, replacing conventional cytotoxics. #sabcs2022

Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer medpagetoday.com/meetingcoverag…

A #breastcancer diagnosis doesn’t have to upend your whole life! A special thanks to Perlmutter Cancer Center at NYU Langone Health’s Dr. Doug Marks (L) & Kathie Joseph, MD, MPH(kathiejosephmd.bsky.social) for joining NYU Langone Health’s Mark B. Pochapin, MD (R) on #ChiefsRounds! Missed our conversation? SiriusXM.us/DoctorRadio to listen on your schedule!